- Home
- NKSH vs ADAP Comparison
NKSH vs ADAP Comparison
Compare NKSH & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- ADAP
- Stock Information
- Founded
- NKSH 1891
- ADAP 2008
- Country
- NKSH United States
- ADAP United Kingdom
- Employees
- NKSH N/A
- ADAP N/A
- Industry
- NKSH Major Banks
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- NKSH Finance
- ADAP Health Care
- Exchange
- NKSH Nasdaq
- ADAP Nasdaq
- Market Cap
- NKSH 180.8M
- ADAP 158.6M
- IPO Year
- NKSH N/A
- ADAP 2015
- Fundamental
- Price
- NKSH $29.14
- ADAP $0.58
- Analyst Decision
- NKSH Strong Buy
- ADAP Strong Buy
- Analyst Count
- NKSH 1
- ADAP 4
- Target Price
- NKSH $38.00
- ADAP $2.79
- AVG Volume (30 Days)
- NKSH 14.2K
- ADAP 2.3M
- Earning Date
- NKSH 10-24-2024
- ADAP 03-05-2025
- Dividend Yield
- NKSH 5.18%
- ADAP N/A
- EPS Growth
- NKSH N/A
- ADAP N/A
- EPS
- NKSH 1.44
- ADAP N/A
- Revenue
- NKSH $43,450,000.00
- ADAP $175,041,000.00
- Revenue This Year
- NKSH N/A
- ADAP $204.91
- Revenue Next Year
- NKSH $19.72
- ADAP N/A
- P/E Ratio
- NKSH $20.17
- ADAP N/A
- Revenue Growth
- NKSH N/A
- ADAP 146.27
- 52 Week Low
- NKSH $26.00
- ADAP $0.53
- 52 Week High
- NKSH $35.00
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- NKSH 51.10
- ADAP 41.87
- Support Level
- NKSH $26.00
- ADAP $0.55
- Resistance Level
- NKSH $29.66
- ADAP $0.65
- Average True Range (ATR)
- NKSH 0.94
- ADAP 0.05
- MACD
- NKSH 0.18
- ADAP 0.00
- Stochastic Oscillator
- NKSH 85.79
- ADAP 31.31
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.